Publications by authors named "Larry Schaaf"

Claim this Profile
P
Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats.
Zhiliang Xie, Min Chen, Swagata Goswami, Rajes Mani, Dasheng Wang, Larry J Schaaf

AAPS J· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of Dabrafenib and Pazopanib in Mutated Advanced Malignancies.
Sigurdis Haraldsdottir, Filip Janku, Ming Poi, Cynthia Timmers, Susan Geyer, Larry J Schaaf

JCO Precis Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Miguel A Villalona-Calero, Wenrui Duan, Weiqiang Zhao, Konstantin Shilo, Larry J Schaaf

J Natl Cancer Inst· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer.
Daniel H Ahn, Junan Li, Lai Wei, Austin Doyle, John L Marshall, Larry J Schaaf

Sci Rep· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
Alison R Walker, Rebecca B Klisovic, Ramiro Garzon, Larry J Schaaf, Kristina Humphries

Leuk Lymphoma· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Amita Patnaik, Kyriakos P Papadopoulos, Anthony W Tolcher, Muralidhar Beeram, Saïk Urien, Larry J Schaaf

Cancer Chemother Pharmacol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.
Ewa Mrózek, Rachel Layman, Bhuvaneswari Ramaswamy, Larry Schaaf, Xiaobai Li

Clin Breast Cancer· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.
Elaine T Lam, Sanjay Goel, Larry J Schaaf, Gillian F Cropp, Alison L Hannah

Cancer Chemother Pharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
Craig C Hofmeister, Xiaoxia Yang, Flavia Pichiorri, Ping Chen, Darlene M Rozewski, Larry J Schaaf

J Clin Oncol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
William Blum, Rebecca B Klisovic, Heiko Becker, Xiaoxia Yang, Darlene M Rozewski, Larry Schaaf

J Clin Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
William Blum, Mitch A Phelps, Rebecca B Klisovic, Darlene M Rozewski, Wenjun Ni, Larry J Schaaf

Haematologica· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Bhuvaneswari Ramaswamy, Tanios Bekaii-Saab, Larry J Schaaf, Gregory B Lesinski, David M Lucas

Cancer Chemother Pharmacol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
William Blum, Ramiro Garzon, Rebecca B Klisovic, Sebastian Schwind, Alison Walker, Larry Schaaf

Proc Natl Acad Sci U S A· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Thomas S Lin, Kristie A Blum, Diane Beth Fischer, Sarah M Mitchell, Amy S Ruppert, Larry J Schaaf

J Clin Oncol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
Thomas S Lin, Amy S Ruppert, Amy J Johnson, Beth Fischer, Nyla A Heerema, Larry J Schaaf

J Clin Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Mitch A Phelps, Thomas S Lin, Amy J Johnson, Eunju Hurh, Darlene M Rozewski, Larry J Schaaf

Blood· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.
Islam R Younis, Samuel Malone, Henry S Friedman, Larry J Schaaf, William P Petros

Cancer Chemother Pharmacol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
Qing Liu, Katherine L Farley, Amy J Johnson, Natarajan Muthusamy, Craig C Hofmeister, Larry J Schaaf

Ther Drug Monit· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
Donghua Yin, Franzanne Vreeland, Larry J Schaaf, Robert Millham, Barbara A Duncan

Clin Cancer Res· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Miguel Villalona-Calero, Larry Schaaf, Gary Phillips, Gregory Otterson, Kevin Panico

Cancer Chemother Pharmacol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
John C Byrd, Thomas S Lin, James T Dalton, Di Wu, Mitch A Phelps, Larry J Schaaf

Blood· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Henry C Pitot, Alex A Adjei, Joel M Reid, Jeff A Sloan, Pamela J Atherton, Larry J Schaaf

Cancer Chemother Pharmacol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Larry J Schaaf, Lisa A Hammond, Stuart J Tipping, Richard M Goldberg, Rakesh Goel

Clin Cancer Res· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Albert Craig Lockhart, Gillian F Cropp, Jordan D Berlin, Edwin Donnelly, Robert D Schumaker, Larry J Schaaf

Am J Clin Oncol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.
J Paul Monk, Gary Phillips, Ross Waite, John Kuhn, Larry J Schaaf

J Clin Oncol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis